DBV TECHNOLOGIES |
Market Closed -
Other stock markets
|
After market 02:59:20 pm | |||
| 1.252 EUR | -1.42% |
|
1.246 | -0.48% |
| Sales 2024 * | 6.53M 6.97M | Sales 2025 * | 4.89M 5.21M | Capitalization | 122M 130M |
|---|---|---|---|---|---|
| Net income 2024 * | -107M -114M | Net income 2025 * | -74M -78.89M | EV / Sales 2024 * | -7.39 x |
| Net cash position 2024 * | 170M 182M | Net cash position 2025 * | 224M 239M | EV / Sales 2025 * | -20.8 x |
| P/E ratio 2024 * |
-1.65
x | P/E ratio 2025 * |
-2.96
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies
More press releases
More news
| 1 day | +0.47% | ||
| Current month | -4.13% | ||
| 1 month | -6.18% | ||
| 3 months | -24.94% | ||
| 6 months | -44.33% | ||
| Current year | -30.99% |
1 week
1.25
1.33
1 month
1.251.40
Current year
1.101.90
1 year
1.104.30
3 years
1.1011.70
5 years
1.1025.44
10 years
1.1086.64
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 18-11-28 |
| Director of Finance/CFO | 54 | Nov. 05 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-07-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 21-02-28 |
Michel de Rosen
CHM | Chairman | 73 | 18-06-21 |
Don Soland
BRD | Director/Board Member | 65 | 15-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1.252 | -1.42% | 34 577 |
| 24-04-17 | 1.27 | -0.78% | 39,149 |
| 24-04-16 | 1.28 | -1.08% | 17,499 |
| 24-04-15 | 1.294 | +3.03% | 50,039 |
| 24-04-12 | 1.256 | -1.57% | 36,646 |
Real-time Euronext Paris, April 18, 2024 at 07:04 am EDT
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.27
EUR
Average target price
4.783
EUR
Spread / Average Target
+276.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.99% | 130M | |
| +11.18% | 9.08B | |
| -19.62% | 4.57B | |
| +24.23% | 3.9B | |
| -0.44% | 3.69B | |
| +27.95% | 2.62B | |
| -25.01% | 2.34B | |
| -28.30% | 2.14B | |
| +1.33% | 1.84B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- DBV Stock
